Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
March 25 2024 - 8:30AM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the
“Company”), a specialty pharmaceutical company focused on the
development and commercialization of therapies for the treatment of
neurologic diseases, today announced that it will host a virtual
key opinion leader (“KOL”) event highlighting expert perspectives
on spinal bulbar muscular atrophy (“SBMA”), also known as Kennedy's
Disease, on Thursday, April 4, 2024 at 11:00am ET.
The virtual event will focus on the potential of
AJ201 in SBMA, including KOL perspectives on the SBMA treatment
landscape, an overview of the Phase 1b/2a study evaluating AJ201
for the treatment of SBMA and outcome considerations for the
upcoming topline data read-out for the Phase 1b/2a trial expected
in the second quarter of 2024. The event will be moderated by
Alexandra MacLean, M.D., Chief Executive Officer of Avenue
Therapeutics, and will feature presentations from the following
experts:
- Christopher
Grunseich, M.D., Lasker Clinical Research Scholar and
Investigator and Head of the Inherited Neuromuscular Diseases Unit
at the National Institute of Neurological Disorders and Stroke
- Tahseen Mozaffar,
M.D., Professor of Neurology, Pathology and Laboratory Medicine,
Director of the Division of Neuromuscular Diseases and Director of
the ALS and Neuromuscular Center at the University of California,
Irvine.
To access the conference call, please register
using the audio conference link here. A webcast replay of the event
will be available on the Events page of Avenue’s website at
https://avenuetx.com/.
About Spinal and Bulbar Muscular
Atrophy
Spinal and bulbar muscular atrophy (“SBMA”) is a
rare, X-linked genetic neuromuscular disease primarily affecting
men. The condition is caused by the trinucleotide CAG repeat
expansion in the androgen receptor (“AR”) which leads to production
of a mutant polyglutamine (“polyQ”) AR protein that forms
aggregates responsible for muscular atrophy focused in the limbs
and bulbar region of the body. The weakening of the bulbar muscles
affects chewing, speech and swallowing, with patients prone to
choking or inhaling foods or liquids, resulting in airway
infection. SBMA also affects muscles in the limbs, leading to
difficulty walking and injury caused by falling. Although there is
a range of cited prevalence rates in scientific literature, a
recent study used genetic analysis to estimate disease prevalence
of 1:6,887 males. Currently, there are no treatments approved by
the U.S. Food and Drug Administration or European Medicines Agency
available for patients. For more information about SBMA, also known
as Kennedy’s Disease, please visit
https://kennedysdisease.org/.
About AJ201
AJ201 is a novel, first-in-class asset in
development for the treatment of spinal and bulbar muscular
atrophy. It was designed to modify SBMA through multiple mechanisms
including degradation of the mutant androgen receptor protein and
stimulation of the Nrf1 and Nrf2 pathways, which are involved in
protecting cells from oxidative stress that can lead to cell death.
AJ201 is currently being studied in a Phase 1b/2a multicenter,
randomized, double-blind clinical trial in six clinical sites
across the U.S., which aims to evaluate the safety, PK/PD data and
clinical response of AJ201 in patients suffering from SBMA. AJ201
has been granted Orphan Drug Designation by the FDA for multiple
polyQ diseases, including SBMA, Huntington’s disease and
spinocerebellar ataxia. Avenue exclusively licensed AJ201 from
AnnJi Pharmaceuticals in the United States, Canada, European Union,
Great Britain, and Israel.
About Polyglutamine
diseases
Polyglutamine diseases are a group of
neurodegenerative disorders caused by expanded CAG repeats encoding
a long polyQ tract in the affected proteins. To date, a total of
nine polyQ disorders have been described. Mutant protein
aggregation in affected tissues is the pathological hallmark of
polyQ diseases. Neuroinflammation, oxidative stress and
dysregulated protein quality control are thought to be key
pathological factors that are either direct results of mutant
protein aggregations and/or exacerbate the severity and progression
of the diseases. Modulating multiple cellular pathways in enhancing
degradation of mutant AR aggregates, inducing antioxidant and heat
shock responses, and increasing proteasome expression
simultaneously provide the rationale to develop AJ201 for the
treatment of SBMA and potentially other polyQ diseases.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a
specialty pharmaceutical company focused on the development and
commercialization of therapies for the treatment of neurologic
diseases. It is currently developing three assets including AJ201,
a first-in-class asset for spinal and bulbar muscular atrophy,
BAER-101, an oral small molecule selective GABAA α2, α3 receptor
positive allosteric modulator for CNS diseases, and IV tramadol,
which is in Phase 3 clinical development for the management of
acute postoperative pain in adults in a medically supervised
healthcare setting. Avenue is headquartered in Miami, FL and was
founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more
information, visit www.avenuetx.com.
Forward-Looking Statements
This press release contains predictive or
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of current or historical fact contained in this press
release, including statements that express our intentions, plans,
objectives, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “will,” “should,”
“would” and similar expressions are intended to identify
forward-looking statements. These statements are based on current
expectations, estimates and projections made by management about
our business, our industry and other conditions affecting our
financial condition, results of operations or business prospects.
These statements are not guarantees of future performance and
involve risks, uncertainties and assumptions that are difficult to
predict. Therefore, actual outcomes and results may differ
materially from what is expressed or forecasted in, or implied by,
the forward-looking statements due to numerous risks and
uncertainties. Factors that could cause such outcomes and results
to differ include, but are not limited to, risks and uncertainties
arising from: expectations for increases or decreases in expenses;
expectations for the clinical and pre-clinical development,
manufacturing, regulatory approval, and commercialization of our
pharmaceutical product candidate or any other products we may
acquire or in-license; our use of clinical research centers and
other contractors; expectations for incurring capital expenditures
to expand our research and development and manufacturing
capabilities; expectations for generating revenue or becoming
profitable on a sustained basis; expectations or ability to enter
into marketing and other partnership agreements; expectations or
ability to enter into product acquisition and in-licensing
transactions; expectations or ability to build our own commercial
infrastructure to manufacture, market and sell our product
candidates; acceptance of our products by doctors, patients or
payors; our ability to compete against other companies and research
institutions; our ability to secure adequate protection for our
intellectual property; our ability to attract and retain key
personnel; availability of reimbursement for our products;
estimates of the sufficiency of our existing cash and cash
equivalents and investments to finance our operating requirements,
including expectations regarding the value and liquidity of our
investments; the volatility of our stock price; expected losses;
expectations for future capital requirements; and those risks
discussed in our filings which we make with the SEC. Any
forward-looking statements speak only as of the date on which they
are made, and we undertake no obligation to publicly update or
revise any forward-looking statements to reflect events or
circumstances that may arise after the date of this press release,
except as required by applicable law. Investors should evaluate any
statements made by us in light of these important factors.
Contact: Jaclyn Jaffe Avenue Therapeutics, Inc.
(781) 652-4500ir@avenuetx.com
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Dec 2023 to Dec 2024